Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Müllauer L[au]:

Search results

Items: 1 to 50 of 151

1.

Signet Ring Cell Carcinoma of the Lung: A Diagnostic Pitfall in Pregnancy.

Danzinger S, Köstler WJ, Funovics M, Herac M, Müllauer L, Prosch H, Kölbl H.

Case Rep Obstet Gynecol. 2019 Jun 12;2019:9461579. doi: 10.1155/2019/9461579. eCollection 2019.

2.

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.

Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Class SV, Eisenwort G, Simonitsch-Klupp I, Esterbauer H, Mayerhofer M, Müllauer L, Sperr WR, Valent P, Hoermann G.

Haematologica. 2019 Apr 24. pii: haematol.2019.217950. doi: 10.3324/haematol.2019.217950. [Epub ahead of print]

3.

Results of the extended analysis for cancer treatment (EXACT) trial: a prospective translational study evaluating individualized treatment regimens in oncology.

Prager GW, Unseld M, Waneck F, Mader R, Wrba F, Raderer M, Fuereder T, Staber P, Jäger U, Kieler M, Bianconi D, Hoda MA, Baumann L, Reinthaller A, Berger W, Grimm C, Kölbl H, Sibilia M, Müllauer L, Zielinski C.

Oncotarget. 2019 Jan 29;10(9):942-952. doi: 10.18632/oncotarget.26604. eCollection 2019 Jan 29.

4.

VARIFI-Web-Based Automatic Variant Identification, Filtering and Annotation of Amplicon Sequencing Data.

Krunic M, Venhuizen P, Müllauer L, Kaserer B, von Haeseler A.

J Pers Med. 2019 Feb 1;9(1). pii: E10. doi: 10.3390/jpm9010010.

5.

Feasibility of personalized treatment concepts in gastrointestinal malignancies: Sub-group results of prospective clinical phase II trial EXACT.

Unseld M, Mader R, Baumann L, Veraar C, Wrba F, Waneck F, Kieler M, Bianconi D, Berger W, Sibilia M, Müllauer L, Zielinski C, Prager GW.

Chin J Cancer Res. 2018 Oct;30(5):508-515. doi: 10.21147/j.issn.1000-9604.2018.05.04.

6.

FGF8 induces therapy resistance in neoadjuvantly radiated rectal cancer.

Harpain F, Ahmed MA, Hudec X, Timelthaler G, Jomrich G, Müllauer L, Selzer E, Dörr W, Bergmann M, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B, Silberhumer GR.

J Cancer Res Clin Oncol. 2019 Jan;145(1):77-86. doi: 10.1007/s00432-018-2757-7. Epub 2018 Oct 1.

7.

Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data.

Kranawetter M, Röhrich S, Müllauer L, Obermair H, Reinthaller A, Grimm C, Sturdza A, Köstler WJ, Polterauer S.

Int J Gynecol Cancer. 2018 Jul;28(6):1196-1202. doi: 10.1097/IGC.0000000000001291.

PMID:
29787422
8.

Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome.

Janik S, Raunegger T, Hacker P, Ghanim B, Einwallner E, Müllauer L, Schiefer AI, Moser J, Klepetko W, Ankersmit HJ, Moser B.

Oncotarget. 2018 Apr 24;9(31):21861-21875. doi: 10.18632/oncotarget.25076. eCollection 2018 Apr 24.

9.

Analysis of 10 Adrenocortical Carcinoma Patients in the Cohort of the Precision Medicine Platform MONDTI.

Kieler M, Müllauer L, Koperek O, Bianconi D, Unseld M, Raderer M, Prager GW.

Oncology. 2018;94(5):306-310. doi: 10.1159/000486678. Epub 2018 Feb 14.

PMID:
29444511
10.

Molecular pathology of lung cancer: current status and perspectives.

Oberndorfer F, Müllauer L.

Curr Opin Oncol. 2018 Mar;30(2):69-76. doi: 10.1097/CCO.0000000000000429. Review.

PMID:
29251665
11.

Next generation sequencing: clinical applications in solid tumours.

Müllauer L.

Memo. 2017;10(4):244-247. doi: 10.1007/s12254-017-0361-1. Epub 2017 Nov 3. Review.

12.

Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis.

Greiner G, Gurbisz M, Ratzinger F, Witzeneder N, Simonitsch-Klupp I, Mitterbauer-Hohendanner G, Mayerhofer M, Müllauer L, Sperr WR, Valent P, Hoermann G.

Clin Chem. 2018 Mar;64(3):547-555. doi: 10.1373/clinchem.2017.277897. Epub 2017 Dec 13.

13.

Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.

Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, Lopez de la Fuente O, Choi HS, van der Kouwe E, Gültekin S, Kazianka L, Bigenzahn JW, Hoermann G, Prutsch N, Merkel O, Ringler A, Sabler M, Jeryczynski G, Mayerhoefer ME, Simonitsch-Klupp I, Ocko K, Felberbauer F, Müllauer L, Prager GW, Korkmaz B, Kenner L, Sperr WR, Kralovics R, Gisslinger H, Valent P, Kubicek S, Jäger U, Staber PB, Superti-Furga G.

Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15.

14.

Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.

Thallinger C, Füreder T, Preusser M, Heller G, Müllauer L, Höller C, Prosch H, Frank N, Swierzewski R, Berger W, Jäger U, Zielinski C.

Wien Klin Wochenschr. 2018 Feb;130(3-4):85-91. doi: 10.1007/s00508-017-1285-9. Epub 2017 Nov 2. Review.

15.

Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.

Jeryczynski G, Thiele J, Gisslinger B, Wölfler A, Schalling M, Gleiß A, Burgstaller S, Buxhofer-Ausch V, Sliwa T, Schlögl E, Geissler K, Krauth MT, Nader A, Vesely M, Simonitsch-Klupp I, Müllauer L, Beham-Schmid C, Gisslinger H.

Am J Hematol. 2017 Sep;92(9):885-891. doi: 10.1002/ajh.24788. Epub 2017 Jun 9.

16.

Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis.

Janik S, Bekos C, Hacker P, Raunegger T, Ghanim B, Einwallner E, Beer L, Klepetko W, Müllauer L, Ankersmit HJ, Moser B.

Oncotarget. 2017 Jul 18;8(29):47090-47102. doi: 10.18632/oncotarget.17478.

17.

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.

Valent P, Herndlhofer S, Schneeweiß M, Boidol B, Ringler A, Kubicek S, Gleixner KV, Hoermann G, Hadzijusufovic E, Müllauer L, Sperr WR, Superti-Furga G, Mannhalter C.

Oncotarget. 2017 Apr 4;8(14):23061-23072. doi: 10.18632/oncotarget.15481.

18.

Milestones in pathology-from histology to molecular biology.

Müllauer L.

Memo. 2017;10(1):42-45. doi: 10.1007/s12254-016-0307-z. Epub 2017 Jan 9. Review.

19.

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Gisslinger H, Jeryczynski G, Gisslinger B, Wölfler A, Burgstaller S, Buxhofer-Ausch V, Schalling M, Krauth MT, Schiefer AI, Kornauth C, Simonitsch-Klupp I, Beham-Schmid C, Müllauer L, Thiele J.

Leukemia. 2017 Mar;31(3):774-775. doi: 10.1038/leu.2016.291. No abstract available.

PMID:
28248312
20.

SPAG6 and L1TD1 are transcriptionally regulated by DNA methylation in non-small cell lung cancers.

Altenberger C, Heller G, Ziegler B, Tomasich E, Marhold M, Topakian T, Müllauer L, Heffeter P, Lang G, End-Pfützenreuter A, Döme B, Arns BM, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

Mol Cancer. 2017 Jan 5;16(1):1. doi: 10.1186/s12943-016-0568-5.

21.

Programmed death-ligand 1 expression in rectal cancer.

Jomrich G, Silberhumer GR, Marian B, Beer A, Müllauer L.

Eur Surg. 2016;48(6):352-356. doi: 10.1007/s10353-016-0447-8. Epub 2016 Oct 7.

22.

CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

Greiner G, Witzeneder N, Berger A, Schmetterer K, Eisenwort G, Schiefer AI, Roos S, Popow-Kraupp T, Müllauer L, Zuber J, Sexl V, Kenner L, Sperr WR, Valent P, Mayerhofer M, Hoermann G.

Blood. 2017 Jan 19;129(3):371-382. doi: 10.1182/blood-2016-09-739003. Epub 2016 Nov 16.

23.

Molecular Profiling of Thymoma and Thymic Carcinoma: Genetic Differences and Potential Novel Therapeutic Targets.

Enkner F, Pichlhöfer B, Zaharie AT, Krunic M, Holper TM, Janik S, Moser B, Schlangen K, Neudert B, Walter K, Migschitz B, Müllauer L.

Pathol Oncol Res. 2017 Jul;23(3):551-564. doi: 10.1007/s12253-016-0144-8. Epub 2016 Nov 14.

24.

Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients.

Mayerhoefer ME, Karanikas G, Kletter K, Kiesewetter B, Weber M, Rausch I, Pones M, Simonitsch-Klupp I, Müllauer L, Dolak W, Lukas J, Raderer M.

Clin Nucl Med. 2016 Nov;41(11):837-843.

PMID:
27648705
25.

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm.

Füreder W, Cerny-Reiterer S, Sperr WR, Müllauer L, Jäger E, Schwarzinger I, Geissler K, Valent P.

Wien Klin Wochenschr. 2017 Jun;129(11-12):404-410. doi: 10.1007/s00508-016-1091-9. Epub 2016 Oct 14.

26.

Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer.

Ahmed MA, Selzer E, Dörr W, Jomrich G, Harpain F, Silberhumer GR, Müllauer L, Holzmann K, Grasl-Kraupp B, Grusch M, Berger W, Marian B.

Oncotarget. 2016 Oct 25;7(43):69976-69990. doi: 10.18632/oncotarget.12099.

27.

Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis.

Buxhofer-Ausch V, Gisslinger B, Schalling M, Gleiss A, Schiefer AI, Müllauer L, Thiele J, Kralovics R, Gisslinger H.

Br J Haematol. 2017 Oct;179(1):166-169. doi: 10.1111/bjh.14202. Epub 2016 Jul 19. No abstract available.

PMID:
27432009
28.

HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications.

Janik S, Schiefer AI, Bekos C, Hacker P, Haider T, Moser J, Klepetko W, Müllauer L, Ankersmit HJ, Moser B.

Sci Rep. 2016 Apr 21;6:24267. doi: 10.1038/srep24267.

29.

Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study.

Schiefer AI, Kornauth C, Simonitsch-Klupp I, Skrabs C, Masel EK, Streubel B, Vanura K, Walter K, Migschitz B, Stoiber D, Sexl V, Raderer M, Chott A, da Silva MG, Cabecadas J, Müllauer L, Jäger U, Porpaczy E.

Medicine (Baltimore). 2015 Dec;94(52):e2388. doi: 10.1097/MD.0000000000002388.

30.

Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.

Gisslinger H, Jeryczynski G, Gisslinger B, Wölfler A, Burgstaller S, Buxhofer-Ausch V, Schalling M, Krauth MT, Schiefer AI, Kornauth C, Simonitsch-Klupp I, Beham-Schmid C, Müllauer L, Thiele J.

Leukemia. 2016 May;30(5):1126-32. doi: 10.1038/leu.2015.360. Epub 2015 Dec 29. Erratum in: Leukemia. 2017 Mar;31(3):774-775.

31.

A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma.

Dolak W, Kiesewetter B, Müllauer L, Mayerhoefer M, Troch M, Trauner M, Häfner M, Raderer M, Püspök A.

Surg Endosc. 2016 Jul;30(7):2879-85. doi: 10.1007/s00464-015-4572-4. Epub 2015 Oct 20.

PMID:
26487230
32.

Does Delayed-Time-Point Imaging Improve 18F-FDG-PET in Patients With MALT Lymphoma?: Observations in a Series of 13 Patients.

Mayerhoefer ME, Giraudo C, Senn D, Hartenbach M, Weber M, Rausch I, Kiesewetter B, Herold CJ, Hacker M, Pones M, Simonitsch-Klupp I, Müllauer L, Dolak W, Lukas J, Raderer M.

Clin Nucl Med. 2016 Feb;41(2):101-5. doi: 10.1097/RLU.0000000000001005.

33.

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.

Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Müllauer L, Schwaab J, Hoffmann T, Bradner JE, Radia D, Sperr WR, Hoermann G, Reiter A, Horny HP, Zuber J, Arock M, Valent P.

Leukemia. 2015 Nov;29(11):2230-7. doi: 10.1038/leu.2015.138. Epub 2015 Jun 9.

34.

Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients.

Mayerhoefer ME, Karanikas G, Kletter K, Prosch H, Kiesewetter B, Skrabs C, Porpaczy E, Weber M, Knogler T, Sillaber C, Jaeger U, Simonitsch-Klupp I, Ubl P, Müllauer L, Dolak W, Lukas J, Raderer M.

Clin Cancer Res. 2015 Jun 1;21(11):2506-13. doi: 10.1158/1078-0432.CCR-14-2454. Epub 2015 Mar 2.

35.

FISH Technique as Additional Diagnostic Tool in Differentiating Testicular Pulmonary Metastasis from Pulmonary Congenital Cystic Adenomatoid Malformation.

Komina S, Herac M, Müllauer L, Mazal PR, Susani M.

Appl Immunohistochem Mol Morphol. 2016 Mar;24(3):e16-7. doi: 10.1097/PAI.0000000000000131. No abstract available.

PMID:
25611239
36.

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.

Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, Müllauer L, Baumgartner S, Beham-Schmid C, Sperr WR, Mannhalter C, Sill H, Linkesch W, Arock M, Hartmann K, Valent P.

Oncotarget. 2015 Feb 20;6(5):3071-84.

37.

Adenocarcinoma of the thymus, enteric type: report of 2 cases, and proposal for a novel subtype of thymic carcinoma.

Moser B, Schiefer AI, Janik S, Marx A, Prosch H, Pohl W, Neudert B, Scharrer A, Klepetko W, Müllauer L.

Am J Surg Pathol. 2015 Apr;39(4):541-8. doi: 10.1097/PAS.0000000000000359. Review.

PMID:
25517960
38.

DNA methylation transcriptionally regulates the putative tumor cell growth suppressor ZNF677 in non-small cell lung cancers.

Heller G, Altenberger C, Schmid B, Marhold M, Tomasich E, Ziegler B, Müllauer L, Minichsdorfer C, Lang G, End-Pfützenreuter A, Döme B, Arns BM, Fong KM, Wright CM, Yang IA, Klepetko W, Zielinski CC, Zöchbauer-Müller S.

Oncotarget. 2015 Jan 1;6(1):394-408.

39.

The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB.

Anees M, Horak P, Schiefer AI, Vaňhara P, El-Gazzar A, Perco P, Kiesewetter B, Müllauer L, Streubel B, Raderer M, Krainer M.

Leuk Lymphoma. 2015 May;56(5):1440-9. doi: 10.3109/10428194.2014.953149. Epub 2014 Nov 5.

PMID:
25248880
40.

Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.

Valent P, Berger J, Cerny-Reiterer S, Peter B, Eisenwort G, Hoermann G, Müllauer L, Mannhalter C, Steurer M, Bettelheim P, Horny HP, Arock M.

Ann Hematol. 2015 Feb;94(2):223-31. doi: 10.1007/s00277-014-2207-9. Epub 2014 Sep 11.

41.

ROS1 mutation and treatment with crizotinib in a 30-year old Caucasian woman with stage IV non-small cell lung cancer/adenocarcinoma and complete remission.

Blaukovitsch M, Hofer J, Hutarew G, Müllauer L, Ingrid SK, Studnicka M.

Thorac Cancer. 2014 Sep;5(5):455-9. doi: 10.1111/1759-7714.12106. Epub 2014 Aug 25.

42.

Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients.

Kiesewetter B, Lukas J, Kuchar A, Mayerhoefer ME, Streubel B, Lagler H, Müllauer L, Wöhrer S, Fischbach J, Raderer M.

PLoS One. 2014 Jul 31;9(7):e104004. doi: 10.1371/journal.pone.0104004. eCollection 2014.

43.

Clarithromycin Leading to Complete Remission in the First-Line Treatment of Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma.

Kiesewetter B, Lukas J, Kuchar A, Mayerhoefer ME, Müllauer L, Raderer M.

J Clin Oncol. 2015 Dec 10;33(35):e130-2. doi: 10.1200/JCO.2013.49.8006. Epub 2014 Apr 28. No abstract available.

PMID:
24778391
44.

CD52 is a molecular target in advanced systemic mastocytosis.

Hoermann G, Blatt K, Greiner G, Putz EM, Berger A, Herrmann H, Cerny-Reiterer S, Gleixner KV, Walz C, Hoetzenecker K, Müllauer L, Reiter A, Sotlar K, Sexl V, Valent P, Mayerhofer M.

FASEB J. 2014 Aug;28(8):3540-51. doi: 10.1096/fj.14-250894. Epub 2014 Apr 23.

PMID:
24760752
45.

Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.

Moser B, Janik S, Schiefer AI, Müllauer L, Bekos C, Scharrer A, Mildner M, Rényi-Vámos F, Klepetko W, Ankersmit HJ.

PLoS One. 2014 Apr 4;9(4):e94118. doi: 10.1371/journal.pone.0094118. eCollection 2014.

46.

Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients.

Mayerhoefer ME, Karanikas G, Kletter K, Prosch H, Kiesewetter B, Skrabs C, Porpaczy E, Weber M, Pinker-Domenig K, Berzaczy D, Hoffmann M, Sillaber C, Jaeger U, Müllauer L, Simonitsch-Klupp I, Dolak W, Gaiger A, Ubl P, Lukas J, Raderer M.

Clin Cancer Res. 2014 Jun 1;20(11):2984-93. doi: 10.1158/1078-0432.CCR-13-3355. Epub 2014 Apr 2.

47.

Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis.

Wöhrer S, Kiesewetter B, Fischbach J, Müllauer L, Troch M, Lukas J, Mayerhoefer ME, Raderer M.

Ann Hematol. 2014 Aug;93(8):1287-95. doi: 10.1007/s00277-014-2042-z. Epub 2014 Mar 15.

PMID:
24633660
48.

Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemia.

Buxhofer-Ausch V, Olcaydu D, Gisslinger B, Schalling M, Frantal S, Thiele J, Müllauer L, Kvasnicka HM, Watzke H, Kralovics R, Gisslinger H.

Eur J Haematol. 2014 Aug;93(2):103-11. doi: 10.1111/ejh.12307. Epub 2014 Apr 23.

PMID:
24617727
49.

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H.

Valent P, Blatt K, Eisenwort G, Herrmann H, Cerny-Reiterer S, Thalhammer R, Müllauer L, Hoermann G, Sadovnik I, Schwarzinger I, Sperr WR, Mannhalter C, Horny HP.

Leuk Res Rep. 2013 Nov 26;3(1):8-13. doi: 10.1016/j.lrr.2013.11.001. eCollection 2014.

50.

Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.

Valent P, Cerny-Reiterer S, Hoermann G, Sperr WR, Müllauer L, Mannhalter C, Pehamberger H.

Am J Blood Res. 2014 Dec 15;4(2):93-100. eCollection 2014.

Supplemental Content

Loading ...
Support Center